Nasdaq

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...
NC Biotech

Charlotte’s Milestone Pharmaceuticals gains FDA approval for heart drug

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...
Seeking Alpha

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil ...
Taiwan News

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
Seeking Alpha

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

MONTREAL and CHARLOTTE, N.C., Nov. 7, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November ...
WKRG

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

MONTREAL and CHARLOTTE, N.C., Nov. 11, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and ...
Finanznachrichten

Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...